In the lab
A gentler approach to genome editing
CRISPR genome editing, for all its utility, relies on cutting into strands of DNA, a prospect that can limit its benefits for certain diseases and lead to problematic off-target edits. Feng Zhang, the Broad Institute's resident CRISPR pioneer, co-founded a company to push forward a less violent approach to tinkering with the genome.
As STAT's Allison DeAngelis reports, the company is called Moonwalk Therapeutics, and the idea is epigenetic editing. Where most genome editing technologies are aimed at DNA itself, Moonwalk is targeting the surrounding chemical compounds that impact gene expression, crafting medicines that might switch genes on and off without making permanent changes to DNA.
Among Zhang's co-founders is Alex Aravanis, who helped start the blood testing firm Grail and will serve as CEO. The company's funding syndicate includes Alpha Wave Ventures, Arch Venture Partners, and Khosla Ventures.
Read more.
Beyond GLP-1
Novo is looking for weight-loss drugs on the cutting edge
Novo Nordisk, maker of the blockbuster obesity treatment Wegovy, has a long-term vision of revolutionizing the treatment of metabolic disease. Getting there is going to require turning some speculative science into effective medicines.
In obesity, that means turning to genome editing. Novo said today that it has partnered with Omega Therapeutics, a Flagship Pioneering company, to develop a novel therapy that would manipulate a person's DNA to effectively turn up the heat and burn energy, thereby leading to weight loss. In MASH, the prevalent, obesity-related liver disease, Novo is working with another Flagship startup called Cellarity in search of a small-molecule drug.
Each deal is relatively small, adding up to a potential $1 billion if both companies hit certain milestones. But each adds to Novo's growing mosaic of potential medicines that might succeed Wegovy and Ozempic, including RNA-based treatments, cannabinoid-targeting therapies, and drugs designed to preserve muscle mass during weight loss.
Read more.
Markets
The first test of 2024's IPO waters
Last year's biotech rebound brought a boost in dealmaking, gains for biotech stocks, and a few massive venture capital rounds for newfangled startups. But IPOs, an integral part of the industry's financial ecosystem, got left behind in 2023, which saw the fewest biotech companies go public in a decade.
We'll soon find out whether 2024 will be different. First up is CG Oncology, which filed its IPO paperwork with the SEC yesterday. The company, headquartered in Irvine, Calif., is in Phase 3 with a treatment for bladder cancer, enrolling patients who have already tried the standard of care. The drug, called cretostimogene, is CG's only pipeline asset.
CG doesn't exactly have the markings of a bellwether biotech IPO. The company's list of investors doesn't include any of the industry's name-brand VCs, and it had just $10 million in cash as of Sept. 30. But its success or failure going public will provide a potentially instructive datapoint in a year that is likely to see many more startups attempting IPOs.
No comments